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Abstract
The course of preclinical pain symptoms sheds light on the etiology and prognosis of chronic pain.
We aimed to quantify rates of developing initial- and recurrent-symptoms of painful
temporomandibular disorder (TMD) and to evaluate associations with health behaviors. In the
OPPERA prospective cohort study, 2,719 people aged 18-44 years with lifetime absence of TMD
when enrolled completed 25,103 quarterly (three-monthly) questionnaires during amedian 2.3-
year follow-up period. Questionnaires documented TMD symptom episodes, headache, other body
pain, health care attendance and analgesic usage and. Kaplan-Meier methods for clustered data
estimated symptom-free survival time. Multivariable models assessed demographic variation in
TMD symptom rates and evaluated associations with healthcare and analgesic use. One third of
people developed TMD symptoms and for one quarter of symptomatic episodes, pain intensity
was severe. Initial TMD symptoms developed at anannual rate of 18.8 episodes per 100 people.
The annual rate more than doubled for first-recurrence and doubled again for second-or-
subsequent recurrence such that, one year after first recurrence, 71% of people experienced second
© 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Corresponding author: Gary D. Slade, BDSc, DDPH, PhD, Department of Dental Ecology, Koury Oral Health Sciences, Room 4501E,
UNC School of Dentistry, 385 South Columbia Street, CB#7455, USA. Phone: [Int +1] 919-843-0419 gary_slade@dentistry.unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
All other authors declare no financial relationships that might represent a possible conflict of interest.
NIH Public Access
Author Manuscript
Pain. Author manuscript; available in PMC 2014 May 01.
Published in final edited form as:













recurrence. The overall rate increased with age and was greater in African-Americans and lower in
Asians relative to Whites. The probability of TMD symptoms was strongly associated with
concurrent episodes of headache and body pain and with past episodes of TMD symptoms.
Episodes of TMD symptoms, headache and body pain were associated with increases of ~10% in
probability of analgesic usage and healthcare attendance. Yet, even when TMD, headache and
body pain occurred concurrently, 27% of people neither attended healthcare nor used analgesics.
Keywords
temporomandibular disorder; epidemiology; pain symptoms; prospective cohort study; health
behavior
Introduction
Individuals may experience pain and related symptoms long before a pain condition is
diagnosed clinically. These early symptoms may be a preclinical stage in the development of
a chronic pain condition that is of prognostic significance. Other symptoms are self-limiting
episodes of no consequence. In either scenario, pain symptoms may be singular or recurrent;
transient or persistent; mild or severe; and isolated or coexistent with other pain symptoms.
Pain intensity may escalate with each episode and their effects might accumulate, such that
presence of one preclinical pain symptom contributes to risk of developing a new pain
condition[28,30]. Indeed, many people with chronic pain have manifestations that overlap
with two or more clinical classifications, although some regional pain conditions have
distinctive natural histories. [5] Knowledge about the course of preclinical pain symptoms
offers potential for new opportunities to prevent chronic pain.
Longitudinal data regarding pain symptoms are mostly confined to measurement at two
points in time. Such studies are informative of risk of onset[19]. For example, in a
prospective cohort study of adults aged 18–75 years who were free of orofacial pain on
enrollment, 4.6% developed symptoms after two years[2]. Such studies are also informative
of prognosis. Among 14 participating countries in a World Health Organization study of
persistent pain syndromes, 49% of those with a persistent pain condition at enrollment had
not recovered 12 months later[12].
However, studies limited to two time points may inadequately measure trends and fail to
observe variability in temporal patterns of pain episodes. In a study of orofacial pain that
followed adolescents every three months for three years, 10% of adolescents showed a
stepwise pattern of increasing facial pain symptoms over time[9]. The Doetinchem Cohort
Study evaluated the 10-year course of low back pain symptoms in an adult population
(n=4,007) collecting data on three occasions[29]. Despite stable prevalence over time, the
substantial variation in new episodes, recovery, recurrence and long-standing pain led
investigators to describe the course of back pain as “a challenge for epidemiological studies”
[29](p.998). Similarly, data collected on knee pain at four time points over 12 years showed
substantial temporal fluctuation in symptoms[28].
Preclinical pain symptoms are part of the medical “symptom iceberg,”[13] referring to
symptoms that are not managed by healthcare professionals. In a 1988 survey of oral and
facial pain, only 44% of those who reported pain symptoms had sought professional
attention for their pain[20]. Population-based epidemiological studies are well suited to
investigate preclinical pain symptoms which, by definition, are not observed among patients
in clinical settings. The four aims of this investigation are to:
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1. Describe demographic variation in the rate of developing TMD pain symptoms
prior to clinical diagnosis;
2. Estimate time-to-first-onset and time-to-recurrence of preclinical TMD pain
symptom episodes;
3. Evaluate relationships between preclinical TMD pain symptom episodes and two
other types of pain symptoms: headache and body pain; and
4. Describe associations between all three pain episodes (preclinical TMD pain
symptoms, headache and body pain) and two health behaviors: healthcare
attendance and analgesic usage.
Methods
Results are reported from a prospective cohort study that is part of the OPPERA project
(Orofacial Pain: Prospective Evaluation and Risk Assessment)[21]. This paper investigates
preclinical symptoms prior to development of examiner-classified temporomandibular
disorder (TMD) in OPPERA. “Preclinical” in this study relates to the period “before a
disease becomes clinically recognizable”[1]. The OPPERA prospective cohort study
continuously monitored symptoms during follow-up of study participants and clinically
examined those who reported symptoms. For this study, the preclinical period represented
the period between study enrollment and either classification of TMD by OPPERA
examiners or the end of data collection, whichever came first. This paper does not
investigate predictors of examiner-classified TMD because those findings will be reported in
other papers from the OPPERA project.
Methods for the parent OPPERA project are described elsewhere[27]. Methods relevant to
this investigation are summarized below and additional details appear in the Supplementary
materials.
Enrollment of study participants in the OPPERA prospective cohort study
Between May 2006 and November 2008, the OPPERA project enrolled an inception cohort
of 3,263 people with no history of TMD. Enrollment was at four US study sites: Baltimore,
MD; Buffalo, NY; Chapel Hill, NC; and Gainesville, FL. Participants were recruited from
the community using advertisements, emails and flyers explaining that healthy volunteers
aged 18-44 years were needed for a study of muscle and jaw function. Inclusion criteria
were: aged 18-44 years; fluent English language; negative responses to each of 10 questions
about significant medical conditions; no history of facial injury or surgery; not receiving
orthodontic treatment; not pregnant or nursing. Enrollees also met four symptom-history
criteria determined during a screening telephone interview: (i) no orofacial pain in the
preceding month and orofacial pain for no more than four days per month in any preceding
month; (ii) no more than four headaches per month within the preceding three months; (iii)
never diagnosed with TMD; and (iv) no use of a night guard occlusal splint. Two additional
selection criteria were established during a clinical examination based on the Research
Diagnostic Criteria for TMD[10]: (i) pain reported in the examiner-defined orofacial region
for no more than 4 days in the prior 30 days; and (ii) absence of both TMD myalgia and
arthralgia. Human subject or institutional review board approvals were received at all four
study sites and the data coordination center. All study participants provided written,
informed consent before taking part in the study. The OPPERA study is being conducted
under the auspices of a Certificate of Confidentiality (NIDCR-06-17) between the National
Institutes of Health and Dr William Maixner, Principal Investigator of OPPERA. The
Certificate protects the privacy of research subjects.
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At enrollment, telephone interviewers asked about age, gender, race and ethnicity. A
demographic questionnaire asked whether or not participants had lived all of the life in the
United States. A Comprehensive Pain and Symptom Questionnaire[23] (CPSQ) asked about
multiple pain symptoms including “Have you ever had pain in your face, jaw, temple, in
front of the ear, or in the ear, not including toothache or ear infection?”. Other questions in
the CPSQ asked about intensity of headaches during the previous year with response options
being “None”, “Mostly mild, ranging to moderate”, and “Mostly severe, at times moderate”.
People were also asked if they had experienced “other pains that lasted a whole day or more,
or that occurred several times a year due to any cause, and which you still experience”.
Follow-up data collection using three-monthly (hereafter “quarterly”) health update (QHU)
questionnaires
At three-monthly intervals after enrollment, study participants were asked to complete a
quarterly health update (QHU) questionnaire, either online or on paper. In order to capture
an approximate three month period of symptoms, the questionnaire was imprinted with a
person-specific reference date that was 13 weeks prior to the intended completion date.
Questions asked about symptoms experienced in the period since that reference date.
Respondents also recorded the date on which they completed each questionnaire. The
reporting period is defined here as the number of days between the reference date and the
date on which the questionnaire was completed. The intended reporting period was 13
weeks, although its duration varied because some respondents completed the QHU
questionnaire earlier or later than intended.
People and QHU questionnaires used in this analysis
This analysis was limited to 2,719 people who completed 25,103 QHU questionnaires
during follow-up (Supplementary Figure 1). Excluded from analysis were five people found
to be ineligible for enrollment and 521 people who completed no QHU questionnaires.
Individual QHU questionnaires were excluded because the reference period was invalid
(n=257 questionnaires with <30 days or >180 days between the reference date and
completion date), because there were missing responses concerning TMD symptoms (n=760
questionnaires), or because there were missing responses concerning headache or body pain
(n=544 questionnaires). This led to the exclusion of 18 people whose follow-up
questionnaires were invalid (Supplementary Figure 1). In total, 539 people were excluded
due to missing data: 521 who were lost to follow-up, and 18 with invalid questionnaires.
Length of follow-up varied among study participants for three reasons. 1) People were
enrolled during a 30-month window creating 30 months of variation when follow-up for all
of them was closed for analytic purposes in May, 2011. 2) During the follow-up period, 252
symptomatic people were classified as first-onset TMD and hence their subsequent QHU
questionnaires were not used for this study of preclinical symptoms. 3) n=1,534 people
skipped one or more QHU questionnaires, thereby creating a discontinuous period of follow-
up. Most people with discontinuities skipped either one or two QHU questionnaires (n=480
and 318 people, respectively; Supplementary Figure 1), although 335 people skipped five or
more QHUs. Hence, follow-up time was computed using the “gap time” method, described
below. This provided the denominator to compute symptom rates, therefore providing valid
estimates of symptom incidence, even for people who completed fewer questionnaires than
intended.
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Classification of pain symptoms and health related behaviors
Three types of symptom episodes were enumerated for each QHU questionnaire. The exact
wording of questions appears in the Supplementary materials, together with findings of test-
retest reliability in reporting symptom episodes.
i. A TMD symptom episode was defined as a reporting period (defined above) in
which orofacial pain for at least 5 consecutive days per month was reported for one
or more months. Five days per month was used as the threshold because it
exceeded the frequency of TMD symptoms that was permitted at enrollment. This
allowed us to classify such TMD symptom episodes as “new” events, which is an
important requirement when describing incidence in an inception cohort.-TMD
symptom episodes were classified using only these reported symptoms; findings
from clinical examinations were not used in this analysis.
ii. An episode of headache was defined as a reporting period in which at least five
headaches were reported in the preceding month. Five times per month was used as
the threshold because it exceeded the frequency of headaches permitted when
enrolling the cohort.
iii. An episode of bodily pain was defined as a reporting period in which ache(s) or
pain(s) lasting one day or more were reported in one or more of the following
locations: abdomen, arms, back, chest, feet, hands, hips, legs, neck or shoulders.
One or more days was used as the threshold for reporting other body symptoms
because the underlying focus of this paper, the symptom iceberg, applies to pain
conditions of varying duration that can occur in the rest of the body. This threshold
provided a more inclusive depiction of what people report. In metaphoric terms, it
allows a better estimate of how deep the bottom of the iceberg might extend. For
each anatomical location listed in the questionnaire, respondents were asked to
check all that applied.
When reporting TMD symptoms, people rated the intensity of the pain using an 11-point
numeric rating scale (0: no pain; 10: worst pain imaginable) [15,16]. Whether or not pain
symptom episodes were reported, people were also asked if they had visited a physician,
dentist, chiropractor or any other type of healthcare provider during the reporting period.
However, the reason for the visit was not queried. Those who reported having made a visit
were asked if the healthcare provider told them that they had “Temporomandibular Muscle
and Joint Disorder, TMJD, TMD, or TMJ”. Each QHU questionnaire also inquired if
respondents were taking pain medications, whether or not these were prescribed by a doctor.
Data analysis
Except where noted, all data were analyzed using SAS v9.2. Potential biases in loss to
follow-up were investigated by comparing baseline characteristics of people who completed
one or more QHU questionnaires with people who completed no QHU questionnaires. Chi-
square tests for contingency tables were used to evaluate statistical significance of
differences in percentages between groups classified according to demographic
characteristics and history of pain at baseline.
Dependent variables for Aim 1 were the risk of TMD symptom episodes and the rate of
TMD symptom episodes. Risk was defined as the probability of developing a condition,
whereas rate was defined as the frequency of a condition within a defined population within
a specified time period[19]. Each person was classified as having none, one, two, or three or
more episodes, and the percentage of people with one or more episodes represented the risk
of TMD symptom episodes. The rate was computed as the number of symptom episodes
divided by the sum of reference periods queried in QHU questionnaires. The rate was
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expressed as the number of episodes per 100 people per year. Percentages and rates were
computed separately for four demographic groups, classified according to characteristics
reported at baseline: 1) three age categories (18-24 years, 25-34 years, 35-44 years); 2) two
genders; 3) five categories of race/ethnicity (White, Black or African American, Asian,
Hispanic, Other or unstated); and 4) three categories of U.S. residence (lifetime US
residence, less than lifetime US residence, not stated). Multivariable analysis used a
cumulative logistic regression model to evaluate combined effects of demographic
characteristics on odds of successively greater numbers of symptom episodes. For this and
other multivariable models described below, OPPERA study site was an additional
covariate. Demographic variation in the TMD symptom rate was evaluated statistically with
Poisson regression using a generalized estimating equation specifying an independent
working correlation matrix to allow for clustering of potentially multiple episodes within a
person. For each person, the offset variable was the log of the observed follow-up time,
producing parameter estimates for indicator variables that represented the log of the rate
ratio. One or more indicator variables were created for each demographic category after
selecting one category as the referent. Estimates of rate ratios with 95% confidence intervals
(95% CIs) that excluded the null value of 1.0 were judged to be statistically significant.
For Aim 2, investigation of time-to-onset for initial and recurrent episodes was undertaken
with SUDAAN software using its Kaplan-Meier method for survival analysis adapted for
clustered data[33]. Survival analysis is necessary for longitudinal studies where data are
censored. In this study, right-censoring occurred either when a person developed clinically-
diagnosed TMD, was lost to follow-up, or when data collection stopped in May 2011. TMD
diagnosis was included as a censoring criterion because of this paper's focus of preclinical
symptoms. Because people could experience more than one event of TMD symptoms,
survival times were analyzed using methods appropriate for recurrent event data. Risk
intervals were calculated as “gap time” periods and analyzed as restricted risk sets with
event-specific baseline hazards[18]. Specifically, time to an initial episode was defined as
the observed follow-up time from enrollment up to and including the period in which a first
episode of TMD symptoms was reported. If there was no initial episode, the person's
observed follow-up time was the censored survival time. For people who developed one
episode, a second observation was created in the analytic dataset, representing either time to
first recurrence or survival time to censoring. Time to first recurrence was calculated as the
observed follow-up time after the first episode up to and including the period in which a
second episode of TMD symptoms occurred. Otherwise, the observed follow-up time after
the first TMD episode was the censored survival time. The same logic was used to compute
time-to-event or time-to-censoring for second recurrence, creating a third observation in the
dataset for the same person. This process was repeated for third recurrence, fourth
recurrence and so forth, up to the observed maximum of 14 TMD symptom episodes.
Survival functions were then estimated for an initial TMD symptoms episode, first
recurrence, and second or subsequent recurrence. TMD symptom rates were estimate
separately for initial TMD symptoms, first recurrence, and second-or-subsequent recurrence
using the same dataset using a generalized estimating equation Poisson regression model
with the log of gap-time as the offset variable, as described for Aim 1. For example, the rate
of first recurrence was estimated only for people who had initial symptoms, and their gap-
time was the interval between the initial symptom and either first recurrence or censoring.
To address Aim 3, a three-way contingency table was created to cross-classify quarterly
reporting periods according to presence or absence of TMD symptoms, headache, and body
pain, and the counts were plotted in a Venn diagram. The expected number overlapping
symptoms was then calculated using a log-linear model for categorical data, specifying no
interactions among the three types of symptoms. Additional analysis focused on the
proportion of quarterly periods in which TMD symptoms were reported (i.e., risk of TMD
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symptoms) and used the same gap-time dataset used for survival analysis, in which people
could be represented by more than one observation. For descriptive purposes, the risk of
TMD symptoms was reported in quarterly periods classified according to presence or
absence of concurrent headache and body pain during the same quarterly period.
Additionally, risk was reported according to presence or absence of symptoms in the
person's previous quarterly periods and at the time of enrollment. Tests for differences in
risk were evaluated in a multivariable binomial regression model using a generalized
estimating equation with an independent working correlation matrix. The model tested for
contributions of concurrent and previous pain symptoms to risk of TMD symptoms using
quarterly reporting periods as the unit of analysis. People with more than one quarterly
reporting period therefore were represented more than once in the dataset, and indicator
variables were created to signify whether or not the same person reported symptoms in a
previous quarter. An identity link was specified for the model, thereby yielding parameter
estimates for predictor variables that represented attributable risk (i.e., risk difference). This
permitted modeling of additive effects and additive interactions (i.e., synergy), patterns that
were suggested by univariate analysis. Estimates of attributable risk with 95% confidence
intervals (CIs) that excluded the null value of zero were judged to be statistically significant.
Quarterly reporting episodes again were analyzed for Aim 4, focusing on three binary
dependent variables: whether or not the person had reported any of: visited a healthcare
provider; used analgesic medication; or both behaviors during the reporting period. For
descriptive purposes, the percentage of quarters with each health behavior was reported
according to presence or absence of TMD symptoms, headache and body pain during the
same quarterly period and according to participants’ demographic characteristics.
Differences in frequency of health behaviors were evaluated in multivariable binary logistic
regression models using a generalized estimating equation with an independent working
correlation matrix. Predicted probabilities from the model and their associated 95% CIs were
plotted for combinations of eight pain symptoms and for two contrasting demographic
groups selected to illustrate one group with high underlying probabilities of each behavior
(40-year-olds, White, females) and another group with low underlying probabilities of each
behavior (20-year-old Asian males).
Finally, hot deck multiple imputation[3] was used to evaluate the degree of bias created by
loss to follow-up in estimates of symptom rates and rate ratios. The method used five steps.
1) Four characteristics that were associated both with loss to follow-up and with TMD
incidence rate were identified: study site (2 categories: Maryland, all other sites), race/
ethnicity (2 categories: Black/African American, all other race/ethnic groups), baseline
headache history (2 categories: none, mild/severe), and baseline history of body pain (2
categories: yes, no). 2) The complete cohort of 3,258 people enrolled at baseline was cross-
classified according to those four characteristics, creating sixteen strata; 3) For each of the
521 people lost to follow-up, one person was sampled at random from among the people in
the same stratum who provided follow-up data. The method used simple random sampling
with replacement. The sampled person's number of symptom episodes and follow-up period
were used as the imputed estimates for the person lost to follow-up. 4) The imputed records
were added to the records from 2,719 people who had follow-up data, creating a dataset of
3,258 with complete information about symptoms and follow-up period. 5) Steps 3 and 4
were repeated 10 times, with independent random sampling in each replication, and
incidence rates and rate ratios were calculated for each of the 10 replicated datasets. The 10
sets of results were combined using the SAS MIANALYZE procedure to generate valid
estimates of rates, rate ratios and their 95% confidence intervals. Hot deck multiple
imputation was selected from among other possible methods for multiple imputation
because it requires no assumptions about the distribution of variables (which is an important
criterion for the follow-up period, which was censored in this study) and it is not affected by
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model misspecification (which can be a problem with regression-based methods of
imputation.)[3]
Results
The percentage of people who provided follow-up data did not vary significantly according
to baseline characteristics of age, lifetime US residence, or history of orofacial pain
(Supplementary Table 1). However, the percentage was higher in females compared to
males, and was lower in African-Americans compared to other racial/ethnic groups. Also,
the percentage providing follow-up data was greater among people who reported a history of
headache or a history of body pain at enrollment than among people with no such history.
The 2,719 people retained in the cohort completed a median of 9 quarterly health update
questionnaires (QHUs) (range = 1 to 22 QHUs) during a median observed follow-up period
of 2.3 years (range = 0.12 to 5.8 years). The median reporting period for the 25,103 QHU
questionnaires was 83 days and 90% of reporting periods were between 73 and 121 days.
The median number of QHUs and observed follow-up periods were greater for Whites than
for African-Americans, although there were only small differences according to age group,
gender and lifetime US residence (Supplementary Table 2).
Two thirds of people (65.5%) developed no episodes of painful TMD symptoms during
follow-up, while 21.0% developed one episode, 7.7% developed two episodes, and 5.9%
developed three or more episodes. Only 1.8% of people experienced five or more TMD
symptom episodes, and two thirds (66.0%) of the 1,675 TMD symptom episodes were
reported by only one eighth (13.6%) of people in the cohort. The percentage of people
developing one or more TMD pain symptom episodes did not vary markedly according to
the period of follow-up, although among the one quarter of people with fewer than 1.08
years of follow, only 1.18% developed ≥3 symptom episodes, compared to 7% or 8% among
people with longer periods of follow-up (Supplementary Figure 2).
In univariate analysis, both the risk of TMD symptom(s) and the rate were greater in
successively older age groups, in African-Americans relative to Whites, and in lifetime US
residents relative to others (Table 1). The annual TMD symptom episode rate among
females (27.9 episodes per 100 females) did not differ from the rate among males (27.7
episodes per 100 males). Multivariable models confirmed that all four demographic
characteristics were associated independently with odds of successively greater numbers of
incident TMD pain episodes (Supplementary Table 3). Age, race and lifetime US residence,
but not gender, were associated independently with the annual incidence rate of TMD pain
symptoms.
Initial TMD pain symptoms developed at an annual rate of 18.8 episodes per 100 people
(Fig 1A). Following an initial episode, the annual rate of first-recurrence was 52.2 episodes
per 100 people while the annual rate of second- or subsequent-recurrence doubled again, to
109.2 episodes per 100 people. There was corresponding variation in estimated symptom-
free survival time for initial and recurrent episodes of TMD symptoms (Fig 1B). One year
after enrollment, 25% of people in the cohort developed an initial TMD episode. One year
after the initial episode, 49% of people developed first-recurrence, and one year after
recurrence, 71% of people experienced a second or subsequent recurrence of TMD
symptoms. Although not shown in the figures, 1,378 of the 1,675 symptom episodes (82%)
remained preclinical: only 252 episodes led to classification of TMD during clinical
examination by OPPERA examiners and only 45 episodes reportedly were diagnosed as
TMD by a healthcare provider outside of the study.
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More than two thirds of the 1,675 TMD symptom episodes occurred in conjunction with
other pain symptoms, either body pain (n=568 episodes), headache (n=214 episodes) or both
body pain and headache (n=374 episodes) (Fig 2). The observed frequency of combined
symptoms was greater than would have occurred had the three regional symptoms occurred
independently. For example, the combination of all three regional symptoms observed in
374 episodes was more than six times the expected frequency of 58 episodes (Fig 2). Of
note, however, was that in 61% (n=15,418) of the 25,103 reporting periods, none of the
three symptoms was reported.
In unadjusted, univariate analysis of the 25,103 QHU questionnaires, the percentage of
reporting periods with TMD symptoms varied substantially according to concurrent
episodes of headache and bodily pain (Table 2). For example, TMD symptoms were
reported in only 3.3% of quarterly periods when neither headache nor painful body sites
were reported, but increased to 27.0% when there was concurrent headache and concurrent
bodily pain at ≥2 sites. TMD symptom occurrence during one quarterly period also varied
markedly according to the person's history of TMD symptoms in previous quarterly
episodes, from 4.5% for people with no previous TMD symptom episodes, to 27.0% for
people with two or more previous TMD symptoms episodes. The person's symptom history
at baseline was associated with approximately two-fold variation in percentage of painful
TMD episodes during follow-up. TMD pain symptoms had a median pain intensity rating of
5 and interquartile range of 3–7. Those values did not vary appreciably according to
presence or absence of concurrent or prior pain episodes (Table 2). In multivariable analysis
of the data from Table -3, both concurrent headache and body pain were strongly associated
with TMD symptom episodes and they had a small, though statistically significant
(P=0.008) synergistic effect (Table 3). For example, in the absence of concurrent body pain,
headache was associated with an increase of 10.5% in the probability of TMD symptoms,
whereas in the presence of two body sites with concurrent pain, headache was associated
with an increase of 13.7% in the probability of TMD symptoms. A person's experience of
one previous TMD symptom episode was associated with an additional net increase of 5.2%
in probability of TMD symptoms, while two or more previous TMD symptom episodes
were associated with an increase of 16.6% in TMD symptoms. Headache and body pain at
the time of enrollment both were associated with modest increases in probability of TMD
symptoms during follow-up. Because this was a multivariable model, the effects of
concurrent and prior pain episodes were cumulative. For example, compared to risk of 1.9%
in a period where there were no concurrent or prior episodes of TMD or comorbid pain, the
risk of TMD symptoms increased to 35.9% during a reporting period where both headache
(+10.5%), one body site (+1.8%) and their synergistic effects (+1.6%) were experienced by
a person who had two previous TMD symptom episodes (+16.6%) and who, at baseline, had
severe headache (+2.5%) and body pain (+1.0%).
In univariate analysis, analgesic usage, healthcare attendance for any reason, and either
behavior were reported in, respectively, 16.3%, 45.4%, and 51.2% of the quarterly periods
(Table 4). Analgesics usage varied from 8.5% of the quarterly periods where there were no
concurrent pain symptoms (i.e. neither body pain nor headache nor TMD symptoms) to
48.5% of the quarterly periods where all three concurrent pain symptoms were experienced.
The corresponding percentages for healthcare attendance were 39.7% and 55.6%. All three
categories of health behavior were reported by much higher percentages of females than
males and the likelihood of each behavior tended to be greater in older age groups and in
lifetime US residents.
Multivariable models of the data from Table 4 confirmed significant main effects and an
interaction effect of body pain and TMD symptoms (Supplementary Table 4). In the model
for analgesic usage, there was an additional significant (P<0.001) interaction between body
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pain and headache. The nature of the interactions is visible in plots of predicted probabilities
computed from the multivariable models (Figure 3). Combinations of facial pain and
headache were more strongly associated with the probability of each health behavior in the
absence of body pain than they were in the presence of body pain. Additional large
differences in healthcare behaviors were observed between demographic groups (Fig 3). For
a given combination of pain symptoms, there was at least 20% difference in predicted
probability of health behaviors between 20-year-old Asian males and 40-year-old White
females - demographic characteristics selected purposefully to represent high- and low-
underlying likelihood of healthcare behaviors.
Baseline characteristics associated both with greater loss to follow-up (Supplementary Table
1) and symptom incidence (Tables 1 and 2) had effects that varied in direction. For example,
African-Americans were less likely to be retained in the cohort and they had greater
symptom incidence than other races. Meanwhile, people with headache or body pain at
baseline were more likely to be retained in the cohort, although they, too, had greater
symptom incidence than the referent group of people with no such pain at baseline. When
these effects were evaluated simultaneously using multiple imputation, the net effect was a
small change in study outcomes. Specifically, the imputed rate of 28.7 symptoms per annum
(Supplementary Table 5) was only marginally greater than the unimputed rate of 27.8 from
complete-case analysis of people who provided follow-up data (Table 1). Likewise, imputed
and unimputed rate ratios for demographic characteristics differed only at the second
decimal place (Table 1).
Discussion
Key findings
During an average follow-up period of approximately two years, one third of adults in this
study developed TMD symptoms that were rarely diagnosed as clinical TMD, and which
therefore represented a predominantly preclinical iceberg of symptoms in the community.
After developing an initial episode, the TMD symptom rate more than doubled and
following first recurrence, people were more likely than not to experience further recurrence
within 12 months. Nonetheless, only 6% of people in the cohort developed three or more
episodes of TMD symptoms. The overall rate of TMD symptoms was strongly associated
with concurrent episodes of headache and body pain and it varied two-fold according to
some demographic characteristics, although not gender. TMD symptom episodes were
associated with only a 10% increase in probability of healthcare attendance and most
episodes were tolerated without analgesics.
Temporal patterns of TMD symptoms
We used three epidemiological measures to summarize distinctive features of symptom
onset. The first was TMD symptom risk, which summarized individuals’ probability of
developing one or more symptom episode at any stage during follow-up. We further
distinguished between people who experienced one, two or three-or-more TMD symptom
episodes, representing a rudimentary method of clustering individuals according to symptom
density. Our finding that multiple episodes developed in only a small proportion of people is
consistent with results from a cohort study of adolescents where a more sophisticated
method was used to cluster individuals based on temporal trajectories of TMD symptoms[9].
For example, Dunn et al[9] found that most adolescents who developed TMD symptoms
experienced relatively short bursts, while only one in ten experienced symptoms through all
three years of follow-up. In this study, most people who developed TMD symptoms
experienced only one or two episodes, whereas only 6% of people in the cohort developed
three or more episodes.
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The second measure was the rate of TMD symptoms representing the “force of morbidity”
[19] because it considers both the number of symptom episodes and rapidity of their onset.
When evaluating associations with sociodemographic characteristics, there were only subtle
differences between the symptom risk and symptom rate. For example, females had a
slightly greater risk than males of developing 1 or 2 TMD symptom episodes, while the
symptom rate did not differ. This illustrates that symptom occurrence was equivalent when
expressed relative to period of observation, recognizing that women had slightly longer
average periods of follow-up than men. Symptom rates were more informative when
considered for people with recurrent symptoms. For example, the rate of symptoms more
than doubled after an initial episode (Fig 1A). This is an aspect of symptom frequency that
cannot be dissected using a measure of symptom risk.
Survival time, the third measure, provided further insight concerning timing of symptoms.
To allow for more than one episode per person, we used methods that adapt conventional
Kaplan-Meier analysis, permitting repeated observations per person. To our knowledge,
survival analysis has not previously been used to describe temporal patterns of TMD
symptoms, and the findings (Fig 1B) were noteworthy by showing how quickly recurrence
was likely to occur. For example, after experiencing two episodes, 71% of people
experienced further recurrence within 12 months. This represents a useful population
benchmark to formulate advice about prognosis for patients who experience repeated
episodes of TMD symptoms.
In the analysis of symptom risk, we investigated both individuals and reporting periods as
the units of analysis because people and episodes represent distinct populations of interest.
The analysis of reporting periods demonstrated greater-than-chance overlap of headache,
bodily pain and TMD symptoms (Fig 2), consistent with other studies of widespread pain
[6,17] and regional pain [8,11,32]. In multivariable analysis of episodes, risk of TMD
symptoms was elevated when comorbid conditions occurred contemporaneously or prior to
the TMD symptom episode (Table 3). Additionally, risk of TMD symptoms in one episode
was strongly associated with prior episodes of TMD symptoms. Concurrent and prior
episodes of TMD symptoms, headaches and bodily pain had cumulative effects which, in
aggregate, increased risk of TMD symptoms from 2% in the absence of all such episodes to
36% in the presence of all such episodes.
Sociodemographic associations
The overall rate of 27.8 episodes per 100 people, comprising both initial and recurrent
episodes, did not vary substantially according to gender, although age- and racial/ethnic
group differences were large. The general lack of gender variation is consistent with one
other study of preclinical TMD symptoms[31]. In contrast, studies of clinical TMD and
chronic TMD symptoms have observed large gender differences. A Swedish study of
adolescents reported a three-fold greater risk of examiner-diagnosed TMD in girls compared
to boys[22]. In a UK study of chronic orofacial pain symptoms women had more than twice
the risk of developing chronic TMD than men[2]. It is possible that gender has little
influence on development of preclinical symptoms, but that it affects the transition to
clinically-classified TMD or to chronic TMD.
A novel finding was the protective effect of non-lifetime residence in the United States, an
effect which persisted after adjustment for race/ethnicity. In addition to foreign-born
immigrants to the U.S., non-lifetime residence describes native-born Americans who had
lived some time abroad. One explanation of this effect is the healthy migrant phenomenon
by which first-generation immigrants are a selectively healthy group[24,25]. It is plausible
that US-born people who live abroad temporarily might likewise be relatively healthy, and
therefore less prone to pain symptoms.
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As reported in other population-based studies,[20,26] many of these TMD symptom
episodes apparently were not treated, either by healthcare providers or with analgesics. This
is despite the finding that one half of TMD symptom episodes were rated as 5 or higher
using a 0-10 numeric rating scale, consistent with “moderate” pain seen in clinical settings,
and one quarter were rated as 7 or higher, consistent with “severe” clinical pain[4]. Barriers
to healthcare probably represent a small part of the explanation; when enrolled, 81% of
people had health insurance, and 57% had annual household incomes of $40,000 or
more[27]. Instead, answers probably lie in the salience of pain and its impact on people's
daily lives which, together, dictate many aspects of illness behavior[20]. Meanwhile, it was
notable that analgesic usage and healthcare attendance were influenced as much by
demographic characteristics as they were by pain symptoms. This suggests that
demographically-patterned social norms regarding health behaviors also are strong
predictors of whether or not pain is treated.
Study limitations
In prospective cohort studies, loss to follow-up is inevitable and it is likely to cause bias
when the degree of loss is differential, i.e. when it occurs unequally in groups defined by
predictor or outcome variables. However our analysis showed generally non-differential loss
to follow-up (Supplementary Table 2), and when multiple imputation was used to account
for loss to follow-up, it produced negligible changes in symptom rates and rate ratios.
External validity is limited because study participants were not selected at random from the
population. However subjects were recruited from four study sites using multiple
community approaches thereby enhancing representation of major U.S. demographic
groups.[27] Another restriction was our exclusion of people with serious medical conditions,
which probably contributed to underestimation of symptom incidence.
It was surprising that, within a few years, one third of lifetime-asymptomatic adults
developed preclinical TMD symptoms in a . This apparently high rate of TMD symptoms
raises the question of whether people had simply forgotten past episodes when enrolled. The
National Low Back Pain prospective cohort study asked participants to retrospectively recall
various aspects of the pain symptoms that they had prospectively reported a decade earlier.
When validated against initial reports, the overall kappa statistic of 0.37 indicated only
“fair” agreement between initial and recalled pain symptoms[7]. We expect that one feature
of the symptom iceberg is that individuals forget prior episodes of a mild or self-limiting
nature, especially those that occurred many years earlier.
Clinical and public health significance
These findings that many TMD symptoms occur as single episodes support a philosophy of
very conservative clinical management for patients seeking care for initial onset of painful
TMD . Conversely, assigning the label “chronic pain” based only on time since onset of the
presenting condition may underestimate a patient's pain history, as earlier episodes may
have contributed the presenting complaint. The “iceberg” of TMD symptoms found among
one third of people supports the Institute of Medicine's (IOM's) view[14] that the “most
prominent feature of pain that qualifies it as a public health problem is its sheer prevalence”.
While most TMD pain symptom were preclinical, one quarter was of moderate intensity,
and one quarter was severe. If the IOM's emphasis on primary prevention was intended to
target symptoms of this type, interventions would need to overcome the apparent resistance
of people with TMD symptoms to use healthcare. Conversely, among people who can cope
adequately with such symptoms, studies investigating their pain management strategies
might provide new insights and directions for primary prevention strategies.
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One-in-three adults developed TMD symptoms over 2.3 years. Comorbid pain was
common and recurrence was rapid, yet many did not seek healthcare or use analgesics.
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Figure 1. Symptom episode rates and symptom-free survival curves for an initial episode, 1st
recurrence and 2nd or subsequent recurrence of TMD symptoms: OPPERA prospective cohort
study 2006-2011
The rate of TMD symptom episodes (Fig 1A) was calculated using a Poisson regression
generalized estimating equation model that accounted for the correlated data structure
created by potentially-multiple episodes of TMD pain symptoms per person. The numerator
for the rate was the number of painful TMD symptom episodes, and the denominator was
the sum of observed reference periods (in person-years) captured by quarterly (three-
monthly) questionnaires. The model adjusted for OPPERA study site. Observed episode
rates per 100 people per year were 18.8 for first onset, 52.7 for 1st recurrence, and 109.2 for
2nd or later recurrence. Symptom-free survival curves (Fig 1B) are from Kaplan-Meier
estimates calculated with SUDAAN software that make adjustment for the correlated data
structure created for repeated symptom episodes within individuals. For both methods, time
to onset for the initial episode is defined as observed person-years from enrollment to
development of a first-episode of TMD symptoms. Time to onset for a 1st recurrence is
defined as observed person-years from the development of the initial episode to the
development of a second episode. Time to onset of a second recurrence is defined as
observed person-years from the development of the second episode to the development of a
third episode. Similar logic was used for other episodes of recurrence. Estimated
probabilities of symptoms after one year were 0.25 for an initial episode, 0.49 for 1st
recurrence and 0.71 for 2nd or later recurrence. Data for both figures are from 25,103
quarterly questionnaires completed by 2,719 people over a median 2.3 year follow-up period
in the OPPERA prospective cohort study.
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Figure 2. Co-occurrence of regional pain symptoms reported in quarterly reporting periods:
OPPERA prospective cohort study 2006-2011
Data are from 25,103 quarterly (three-monthly) questionnaires completed by 2,719 people
over a median 2.3-year follow-up period in the OPPERA prospective cohort study.
Questionnaires asked about three types of pain symptoms during the preceding three-month
(average) period. Painful TMD symptoms were reports of TMD-like pain lasting ≥5 days
per month for ≥1 month of the reporting period. Headaches are reports of ≥5 headaches
within the most recent month of the reporting period. Body pain was a report of pain in ≥1
of 10 body locations lasting for ≥1 days in the same reporting period. Numbers in white
boxes represent the observed number of episodes. Italicized numbers in square brackets are
the expected number of jointly-occurring pain episodes that would have occurred if each
type of pain episode occurred independently of the other pain episodes.
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Figure 3. Association between three types of pain symptoms and two health behaviors: OPPERA
prospective cohort study 2006-2011
Figure 3: Predicted probabilities of: analgesic usage (Figure 3A) and of healthcare
attendance (Figure 3B) during quarterly periods of follow-up in the OPPERA prospective
cohort study. Predicted probabilities are from binary logistic regression generalized
estimation equation models, shown in Supplementary Table 4. The models estimate
probability of each health-related behavior during the same quarter in which symptoms of
orofacial pain, headache and bodily pain were reported. Models adjust for OPPERA study
site, age (continuous variable), gender (two categories), race/ethnicity (5 categories) and
lifetime US residence (three categories). Predicted probabilities and their 95% confidence
intervals are shown for two contrasting demographic groups, selected to illustrate one group
with high underlying probabilities of each behavior [● 40-year-olds, White, females] and
another group with low underlying probabilities of each behavior [□ 20-year-old Asian
males]. Data are from 25,103 quarterly (three-monthly) questionnaires completed by 2,719
people over a median 2.3 year follow-up period in the OPPERA prospective cohort study.
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Table 2
Univariate associations of concurrent and previous symptom episodes and symptoms at enrollment with
probability of TMD symptoms and pain intensity rating: OPPERA prospective cohort study 2006-2011.
Number of questionnaires n (%) of TMD symptom
episodes
TMD pain intensity (1)
(median [IQR])
All questionnaires 25103 1675 (6.7) 5 [3, 7]
Concurrent pain episodes
Headache Painful body sites
No 0 15937 519 (3.3) 5 [3, 6]
1 3161 231 (7.3) 5 [3, 6]
≥2 3174 337 (11.0) 5 [4, 7]
Yes 0 1428 214 (15.0) 5 [4, 7]
1 568 146 (26.0) 6 [5, 7]
≥2 835 228 (27.0) 6 [4, 7]
Prior quarterly episodes
TMD symptom episodes
    0 20822 939 (4.5) 5 [3, 7]
    1 2919 369 (13.0) 5 [4, 7]
    ≥2 1362 367 (27.0) 5 [4, 7]
Headache episodes
    0 18358 940 (5.1) 5 [3, 7]
    1 3392 347 (10.0) 5 [4, 7]
    ≥2 3353 388 (12.0) 6 [4, 7]
Body pain episodes
    0 19960 1133 (5.7) 5 [3, 7]
    1 2929 269 (9.2) 5 [4, 7]
    ≥2 2214 273 (12.0) 5 [4, 7]
Baseline symptom history
Facial pain No 21353 1289 (6.0) 5 [4, 7]
Yes 3750 386 (10.0) 5 [3, 7]
Body pain No 22263 1379 (6.2) 5 [4, 7]
Yes 2840 296 (10.0) 5 [3, 7]
Headache None 7096 372 (5.2) 5 [4, 7]
Mild 16208 1073 (6.6) 5 [3, 7]
Severe 1799 230 (13.0) 6 [5, 7]
(1) From 0-10 numerical rating scale of pain intensity reporting during quarterly period in which TMD symptom episodes were experienced. IQR =
interquartile range. Data are from 25,103 quarterly (three-monthly) questionnaires completed by 2,719 people over a median 2.3 year follow-up
period in the OPPERA prospective cohort study.
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Table 3
Multivariable associations of concurrent and previous symptom episodes and symptoms at enrollment with
risk of TMD symptoms: OPPERA prospective cohort study 2006-2011.
Risk predictor TMD symptom probability (%) and 95%CL (1) P-value (2)
Reference probability(3) 1.9 1.4 ,2.5 <0.001
Additive probability (4) associated with concurrent symptom episodes
    Headache (ref=None) 10.5 8.7 ,12.3 <0.001
    Number of painful body sites 1.8 1.5 ,2.2 < 0.001
    Synergy: headache and body pain 1.6 0.4 ,2.9 0.008
Additive probability associated with previous TMD symptom episodes
    1 episode (ref=None) 5.2 4.0 6.5 <0.0001
    ≥2 episodes (ref=None) 16 .6 13.1 20.2 <0.0001
Additive probability associated with baseline pain history
    Mild headache (ref=None) 0.5 0.1 ,0.9 0.030
    Severe headache (ref=None) 2.5 1.0 ,3.9 0.001
    Body pain (ref=None) 1.0 0.0 ,2.0 0.044
1)Except as noted for footnote 3 and 4, estimates represent attributable risk (i.e. additive risk difference) of TMD symptoms associated with each
risk predictor. Probabilities were estimated using multivariable log-binomial, generalized estimating equation model, specifying an identity link
function to model attributable risk of TMD symptoms associated concurrent and past symptoms. The model adjusts for correlation created by
multiple observations per person. The multivariable model contained all the concurrent and past symptoms shown in the table, as well as indicator
variables for OPPERA study site. Data were 25,103 quarterly (three-monthly) questionnaires completed by 2,719 people over a median 2.3-year
follow-up period in the OPPERA prospective cohort study. 95%CL = 95% confidence limits. Confidence limits that exclude the null value of zero
show statistically significant additive effects of the relevant symptom on probability of TMD symptoms.
2)P-values are from score statistics from generalized estimating equation analysis of multivariable, log-binomial regression models. The P-value
tests the null hypothesis that the estimated additive or synergistic effect equals zero.
3)Estimated probability of TMD symptom episodes per quarterly reporting period in people who had none of the headache or body pain symptoms
reported for the same quarterly period.
4)The additional probability of TMD pain symptom episodes due to synergy (additive interaction) between concurrent headache and number of
painful body sites.


























































































































































































































































































































































































































































































































































































































Pain. Author manuscript; available in PMC 2014 May 01.
